Literature DB >> 18774098

Design and implementation of a population-based registry of Implantable Cardioverter Defibrillators (ICDs) in Ontario.

Douglas S Lee1, David Birnie, Douglas Cameron, Eugene Crystal, Paul Dorian, Lorne J Gula, Jeffrey S Healey, Amir Janmohammed, Yaariv Khaykin, Andrew D Krahn, Catherine LeFeuvre, Christopher S Simpson, Raymond Yee, Judy Hardy, Pamela M Slaughter, Zhongliang Chen, David A Alter, Andreas Laupacis, Jack V Tu.   

Abstract

BACKGROUND: There are scarce population-based data on the use, complication rates, and outcomes of patients receiving implantable cardioverter defibrillators (ICDs).
OBJECTIVE: This study sought to describe the methodology of the Ontario ICD Database, a prospective study of all ICD recipients in Ontario, Canada.
METHODS: In this registry, web-based data collection will be performed in all patients referred to a cardiac electrophysiologist for consideration of an ICD. The variables included in the database were determined by consensus. Outcomes to be assessed will include defibrillator device therapies (e.g., shock or antitachycardia pacing), morbidity, and death. Preliminary statistics are reported after the first 6 months of data collection.
RESULTS: Of 208 total variables selected by consensus, 111 (53.4%) were referral/patient characteristics, 12 (5.8%) were implant-related, and 85 (40.9%) were outcome variables. Among 990 referred patients, 902 were accepted, with the following ICD indications: primary prevention (63.3%), secondary prevention (21.6%), and generator replacement (15.1%). The mean (SD) age of patients with implants was 63.9 +/- 12.6 years, and 79% were men. Among accepted ICD patients, 66% had ischemic heart disease, 23% had nonischemic dilated cardiomyopathy, and 11% had other cardiac conditions. Left ventricular (LV) systolic dysfunction was highly prevalent, with 82% of primary and 44% of secondary prevention patients having LV ejection fraction <or=30%. The perioperative complication rate was 3.69%.
CONCLUSION: The Ontario ICD Database will examine defibrillator patient characteristics and clinical and device-related outcomes. Contemporary ICDs are implanted largely for primary prevention, and the majority of these conformed with LV ejection fraction guidelines.

Entities:  

Mesh:

Year:  2008        PMID: 18774098     DOI: 10.1016/j.hrthm.2008.05.015

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  8 in total

1.  Patients' perspectives on end-of-life issues and implantable cardioverter defibrillators.

Authors:  Patricia H Strachan; Sandra L Carroll; Sonya de Laat; Lisa Schwartz; Heather M Arthur
Journal:  J Palliat Care       Date:  2011       Impact factor: 2.250

2.  Readability and content of patient education material related to implantable cardioverter defibrillators.

Authors:  Patricia H Strachan; Sonya de Laat; Sandra L Carroll; Lisa Schwartz; Katie Vaandering; Gurjit K Toor; Heather M Arthur
Journal:  J Cardiovasc Nurs       Date:  2012 Nov-Dec       Impact factor: 2.083

3.  Seven years of use of implantable cardioverter-defibrillator therapies: a nationwide population-based assessment of their effectiveness in real clinical settings.

Authors:  Arn Migowski; Antonio Luiz Ribeiro; Marilia Sá Carvalho; Vitor Manuel Pereira Azevedo; Rogério Brant Martins Chaves; Lucas de Aquino Hashimoto; Carolina de Aquino Xavier; Regina Maria de Aquino Xavier
Journal:  BMC Cardiovasc Disord       Date:  2015-03-13       Impact factor: 2.298

4.  Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of a prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator.

Authors:  M van Barreveld; M G W Dijkgraaf; M Hulleman; L V A Boersma; P P H M Delnoy; M Meine; A E Tuinenburg; D A M J Theuns; P H van der Voort; G P Kimman; E Buskens; J P G Tijssen; N Bruinsma; T E Verstraelen; A H Zwinderman; P H F M van Dessel; A A M Wilde
Journal:  Neth Heart J       Date:  2017-10       Impact factor: 2.380

5.  Do acute changes in ambient air pollution increase the risk of potentially fatal cardiac arrhythmias in patients with implantable cardioverter defibrillators?

Authors:  Robert Dales; Douglas S Lee; Xuesong Wang; Sabit Cakmak; Mieczyslaw Szyszkowicz; Robin Shutt; David Birnie
Journal:  Environ Health       Date:  2020-06-18       Impact factor: 5.984

6.  Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators.

Authors:  Douglas S Lee; Judy Hardy; Raymond Yee; Jeffrey S Healey; David Birnie; Christopher S Simpson; Eugene Crystal; Iqwal Mangat; Kumaraswamy Nanthakumar; Xuesong Wang; Andrew D Krahn; Paul Dorian; Peter C Austin; Jack V Tu
Journal:  Circ Heart Fail       Date:  2015-07-29       Impact factor: 8.790

7.  Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.

Authors:  Fahad Almehmadi; Andreu Porta-Sánchez; Andrew C T Ha; Hadas D Fischer; Xuesong Wang; Peter C Austin; Douglas S Lee; Kumaraswamy Nanthakumar
Journal:  J Am Heart Assoc       Date:  2017-08-19       Impact factor: 5.501

Review 8.  Remote Monitoring of Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy and Permanent Pacemakers: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2018-10-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.